BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 02/11/25
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone LymphomaBusiness Wire • 02/10/25
Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock DownSeeking Alpha • 02/07/25
Bristol-Myers Squibb Company (BMY) Q4 2024 Earnings Conference Call TranscriptSeeking Alpha • 02/06/25
BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 OutlookZacks Investment Research • 02/06/25
Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q4 EarningsZacks Investment Research • 02/06/25
Bristol Myers Squibb (BMY) Beats Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/06/25
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost CutsBenzinga • 02/06/25
Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%.Investors Business Daily • 02/06/25
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024Business Wire • 02/06/25
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and BreyanziZacks Investment Research • 02/03/25
What Analyst Projections for Key Metrics Reveal About Bristol Myers (BMY) Q4 EarningsZacks Investment Research • 02/03/25
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular CarcinomaBusiness Wire • 01/31/25
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular LymphomaBusiness Wire • 01/31/25
Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 01/30/25